Bain B M, Harrison G, Jenkins K D, Pateman A J, Shenoy E V
Department of Drug Metabolism, Glaxo Group Research Ltd, Greenford, Middlesex, UK.
J Pharm Biomed Anal. 1993 Jul;11(7):557-61. doi: 10.1016/0731-7085(93)80005-l.
Antibodies were produced in rabbits immunized with fluticasone 17-propionate (FP) conjugated to bovine thyroglobulin via its 3-carboxymethoxime with isobutylchloroformate. The antibodies were used to develop a sensitive and specific radioimmunoassay (RIA) for FP in human plasma. The limit of quantitation of the RIA is 50 pg per assay tube. This translates to 50 pg ml-1 plasma when a solid-phase extraction preceded the RIA. The interassay and intraassay relative standard deviations were < 15% in the centre of the assay concentration range rising to < 25% at the lower and upper limits (50 and 250 pg ml-1). No appreciable binding was seen between the antibodies and the metabolite of FP that has been identified in man. The RIA was used to study the time course of plasma concentrations in man following inhalation of FP.
通过将丙酸氟替卡松17 - 酯(FP)与牛甲状腺球蛋白经其3 - 羧基甲肟与异丁基氯甲酸酯偶联,在兔体内产生抗体。这些抗体用于开发一种灵敏且特异的人血浆中FP放射免疫分析法(RIA)。该RIA的定量限为每个测定管50 pg。当在RIA之前进行固相萃取时,这相当于血浆中50 pg ml⁻¹。在测定浓度范围的中心,批间和批内相对标准偏差< 15%,在上下限(50和250 pg ml⁻¹)时升至< 25%。在已在人体中鉴定出的FP代谢物与抗体之间未观察到明显的结合。该RIA用于研究人体吸入FP后血浆浓度的时间进程。